Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192247 | 1.00 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL23384215 | 0.89 | LPAR1 (0.42) | LPAR1LPAR3 | |
| SCHEMBL29948298 | 0.89 | LPAR1 (0.42) | LPAR1LPAR3 | |
| SCHEMBL30309332 | 0.89 | LPAR1 (0.43) | LPAR1LPAR3 | |
| SCHEMBL24867677 | 0.89 | LPAR1 (0.43) | LPAR1LPAR3 | |
| SCHEMBL30191829 | 0.89 | LPAR1 (0.49) | LPAR1LPAR3 | |
| SCHEMBL24867624 | 0.89 | LPAR1 (0.49) | LPAR1LPAR3 | |
| SCHEMBL24867635 | 0.89 | LPAR1 (0.49) | LPAR1LPAR3 | |
| SCHEMBL30192211 | 0.89 | LPAR1 (0.49) | LPAR1LPAR3 | |
| Hydrochloric Acid SCHEMBL30456209 | 0.88 | LPAR1 (0.41) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885 |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.